Loading…
This event has ended. Visit the official site or create your own event on Sched.
Learn the latest cancer care information to benefit your patients and earn up to 30 CNE contact hours! Register now at congress.ons.org.

Sign up or log in to bookmark your favorites and sync them to your phone or calendar.

Industry-Sponsored Events [clear filter]
Wednesday, April 27
 

6:00pm

Empowering Nurses. Improving Safety: Making the Case for Building Safer Systems to Reduce Exposures to Hazardous Drugs
Occupational hazardous drug (HD) exposure is a risk that many oncology nurses encounter daily.  USP<800> standards, published February 1, 2016, will mandate safer systems, including closed-system transfer devices (CSTDs) for HD administration to protect healthcare professionals and patients from unintended exposure. The goal of this session is to empower oncology nurses to lead the transformation in healthcare facilities by providing practical advice and tools from leading experts on safety, HD exposure, and the regulatory environment.

This symposium is provide by an education grant from B Braun Medical

Please click here to register for this event. 

6:00pm

Immunotherapy Grand Rounds (Part 1 of an 8-Part CNE Series): Nursing and Physician Investigators Discuss Cases from Their Practices
This unique symposium focused on the integration of checkpoint inhibitors into general oncology practice is part of an integrated series during which invited nursing faculty members will present actual patient cases from their practices, along with patient-provided lifestyle footage of themselves carrying out daily functions. No didactic presentations will be included, although relevant clinical research and data slides will augment moderated panel discussions designed to assess optimal therapeutic and supportive care strategies for each case. The panel will feature both medical oncologist and nurse experts to ensure that diverse perspectives emerge.

Moderator:
Neil Love, MD

Faculty:

Marianne J Davies, DNP, ACNP-BC, AOCNP-BC
Assistant Professor
Oncology Nurse Practitioner
Yale Cancer Center
New Haven, Connecticut

Roy S Herbst, MD, PhD
Ensign Professor of Medicine (Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, Connecticut



Evan J Lipson, MD
Assistant Professor, Medical Oncology
Melanoma and Cancer Immunology Programs
Johns Hopkins University School of Medicine
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Virginia J Seery, MSN, RN, ANP-BC
Adult Nurse Practitioner
Cutaneous Oncology and Biologics Program
Beth Israel Deaconess Medical Center
Boston, Massachusetts Roy S Herbst, MD, PhD
Yale School of Medicine
New Haven, Connecticut

Evan J Lipson, MD
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Virginia Seery, NP
Beth Israel Deaconess Medical Center
Boston, Massachusetts

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, and Merck.

Please click here to register for this event. 

 
Thursday, April 28
 

6:00am

5-Fluorouracil and Capecitabine Emergencies - Recognition and Treatment of Early Onset Severe Toxicity and Overdose
Learning Objectives:
—- Review the mechanism of action of 5-fluorouracil, and
become familiar with the cytotoxic metabolites that
cause early-onset toxicity.
—- Understand the causes of 5-fluorouracil overdose, and
the “red flags” of unusual, early-onset severe toxicity.
— - Describe how uridine triacetate provides an emergency
treatment for adult and pediatric patients following a
fluorouracil or capecitabine overdose and who exhibit
early-onset, severe or life threatening toxicity.
-— Provide information on the administration of uridine
triacetate oral granules and its limitations of use.

This Non-CNE Symposium is co-sponsored by BTG International Inc. and Wellstat Therapeutics.

Symposia events require separate registration. Please click here to register for this event. 

Thursday April 28, 2016 6:00am - 7:30am
Hemisfair Ballroom 200 E Market St, San Antonio, TX 78205

6:00am

IMBRUVICA® Single-Agent Therapy for Previously Treated Chronic Lymphocyctic Leukemia and Chronic Lymphocytic Leukemia with 17p deletion: A Support and Education Resource for Nursing Professionals*

Please join us for a Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc. presentation of IMBRUVICA® (ibrutinib). Karolina Faysman, NP, RN, MSN, ONP, from UCLA Medical Center, will discuss IMBRUVICA®.


Sponsored by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc

6:00am

Latest Developments in Treating MDS: An Update on Molecular Testing, Low-Risk and High-Risk MDS Therapies, and Disease Management
This breakfast symposium will focus on the role of molecular testing in diagnosing myelodysplastic syndromes (MDS) and targeting treatment; the latest therapy options for low-risk and high-risk MDS patients; and disease management strategies to address quality of life issues and treatment adherence.  Case studies will be used to illustrate the clinical value of molecular testing for MDS, best supportive care options, and care planning. 

This symposium is supported by an independent medical education grant from Celgene Corporation 

Please click here to register for this event.

11:15am

11:15am

Enhancing Patient Care Through Effective Communication
This presentation is designed to help participants enhance patient care by focusing on patient-centered communication functions and skills that can be effectively employed in various types of patient encounters in the cancer care setting.   

© Lilly USA, LLC 2015. ALL RIGHTS RESERVED.

Thursday April 28, 2016 11:15am - 12:15pm
Learning Hall Theater 2 200 E Market St, San Antonio, TX 78205

11:15am

Treating Relapsed/Refractory Multiple Myeloma
A discussion about the challenges in relapsed/refractory multiple myeloma, and a treatment option that may be appropriate to consider for your patients. Learn more about clinical experience, and hear practical dosing and administration recommendations for your patients. 

This program is supported by Celgene Corporation.

Thursday April 28, 2016 11:15am - 12:15pm
Learning Hall Theater 1 200 E Market St, San Antonio, TX 78205

11:15am

Yondelis® (trabectedin) Product Theater
This program is sponsored by Janssen Biotech

Thursday April 28, 2016 11:15am - 12:15pm
Learning Hall Theater 4 200 E Market St, San Antonio, TX 78205

12:15pm

CDK 4/6 Inhibitor Therapy for ER+ Metastatic Breast Cancer - Advancing Nursing Care to Improve Patient Outcomes
Utilizing 3 faculty experts, this symposium will combine interactive lectures and clinical case vignettes to describe the role of CDK 4/6 inhibitors in breast cancer therapy, while highlighting best practices for delivering quality nursing care to patients taking these agents. With a panel discussion session that will allow for lively interactions between experts and learners, this symposium will also solidify take-home points regarding decisions and interactions with patients in routine daily nursing practice.

Supported in part by an educational grant from Pfizer.

Please click here to register for this event.


12:15pm

Gastrointestinal Cancers Grand Rounds (Part 2 of an 8-Part CNE Series): Nursing and Physician Investigators Discuss Cases from Their Practices
This unique symposium focused on the management of colorectal, gastric and pancreatic cancers is part of an integrated series during which invited nursing faculty members will present actual patient cases from their practices, along with patient-provided lifestyle footage of themselves carrying out daily functions. No didactic presentations will be included, although relevant clinical research and data slides will augment moderated panel discussions designed to assess optimal therapeutic and supportive care strategies for each case. The panel will feature both medical oncologist and nurse experts to ensure that diverse perspectives emerge.

Moderator:
Neil Love, MD

Faculty:
Johanna C Bendell, MD
Sarah Cannon Research Institute
Nashville, Tennessee

Philip A Philip, MD, PhD
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

Robin Sommers, DNP, ANP-BC, AOCNP
Dana-Farber Cancer Institute
Boston, Massachusetts

Mandy Wagner, MS, RN, CNP
Nurse Practitioner
The Ohio State University
Columbus, Ohio

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Lilly, Merrimack Pharmaceuticals Inc and Taiho Oncology Inc.

Please click here to register for this event. 

12:15pm

Nursing Opportunities to Improve Outcomes in the Application of Immuno-Oncology Strategies: A Practical Approach to Care
The Nursing Opportunities to Improve Outcomes in the Application of Immuno-Oncology Strategies: A Practical Approach to Care symposium features oncology nurses and physician peers discussing the unique kinetics of response and adverse events with immunotherapies, as well as proactive measures to mitigate and manage immune-related adverse events. Interactive case-based discussions will also allow attendees to apply clinical evidence and expert opinion to patient care scenarios.

Co-Chairs 

Patrick Forde, MD
Assistant Professor of Oncology
Johns Hopkins University
Baltimore, MD   

Joanne Riemer, RN, BSN
Johns Hopkins University
Baltimore, MD 


Faculty 

Jason Luke, MD, FACP
Assistant Professor of Medicine
The University of Chicago Medicine
Chicago, IL  

Karen Matijevich, RN
The University of Chicago Medicine
Chicago, IL 


This activity is supported by educational grants from AstraZeneca.

Please click here to register for this event. 

12:15pm

Updates in Multiple Myeloma: Case Studies in Collaborative Nursing and Patient Care
During the past year, the FDA approved three new myeloma drugs! Please join us for a nursing-oriented, case-based, 1.5 CNE learning opportunity emphasizing nursing implications of new drugs and the latest myeloma research. Practical tool and clinical pearls will be interwoven with shared decision-making and collaborative practice considerations. RSVP today and join the International Myeloma Foundation's Nurse Leadership Board's exceptional nurse speakers for this exciting presentation.

This activity is supported by an educational grant from Amgen, Celgene Corporation, and Takeda Oncology.

Please click here to register for this event.

Thursday April 28, 2016 12:15pm - 1:45pm
Hemisfair Ballroom 200 E Market St, San Antonio, TX 78205

1:45pm

Nursing Considerations in the Neoadjuvant Treatment of HER2+ Breast Cancer
This program is a case based approach regarding the use of a Perjeta+Herceptin based regimen for the treatment of HER2+ neoadjuvant breast cancer.

This program is sponsored by Genentech

Thursday April 28, 2016 1:45pm - 2:45pm
Learning Hall Theater 3 200 E Market St, San Antonio, TX 78205

1:45pm

Overview of Neulasta® (pegfilgrastim) for Injection Delivery Options
Ms. Vicki Tuchman (MS, RN, APN, AOCNS, C.), an Advanced Practice Nurse will provide an educational presentation on the Neulasta Onpro™ delivery option.

This program is presented by Amgen, Inc.

Thursday April 28, 2016 1:45pm - 2:45pm
Learning Hall Theater 1 200 E Market St, San Antonio, TX 78205

1:45pm

Survivorship Care: Implementing the Essentials
This presentation is designed to help participants enhance patient care by recognizing the essential components of survivorship care and how to implement a quality survivorship program in their own clinical setting.

© Lilly USA, LLC 2015. ALL RIGHTS RESERVED.

Thursday April 28, 2016 1:45pm - 2:45pm
Learning Hall Theater 2 200 E Market St, San Antonio, TX 78205

1:45pm

The Oncology Care Landscape: How a Shifting Landscape Contributes to the Complexities of Delivering Quality Cancer Care
Presentation Objectives:    1.  Discuss the landscape shifts in cancer treatment and in healthcare.  Identify how these shifts impact cancer care for the patient.  2.  Define “Financial Toxicity” and discuss its impact on patient care.  3.  Understand the process of insurance approval and how to navigate through the various steps.  4.  Understand how to access advocacy groups on behalf of the patient.  5.  Discuss medication adherence and the collective role of the healthcare team including the specialty pharmacist    

This program is sponsored by Walgreens.

Thursday April 28, 2016 1:45pm - 2:45pm
Learning Hall Theater 4 200 E Market St, San Antonio, TX 78205

6:00pm

Caring for Patients With Metastatic Cancer: Nursing Implications & Overview of a Treatment Option for Metastatic Adenocarcinoma of the Pancreas
Please join us for a Celgene Corporation presentation of Abraxane.  Peter Bjerkerot, RN will walk you through an overview of pancreatic cancer, discuss considerations for the treatment of patients with pancreatic cancer, review updated data regarding the use of Abraxane and provide important safety information. We are looking forward to your attendance.

This program is supported by Celgene Corporation.

6:00pm

CURE® 2016 Extraordinary Healer Award for Oncology Nursing Reception*
Join actor, comedian and cancer advocate Eric Stonestreet from ABC’s Emmy winning series, Modern Family, as CURE® magazine hosts the annual Extraordinary Healer® Award for Oncology Nursing reception.  This inspirational evening full of food and music celebrates the field of oncology nursing and three finalists nominated by readers of CURE® magazine who will be recognized for their compassion, expertise, and excellence in caring for cancer patients and survivors prior announcing this year’s award winner.

Sponsored by CURE® magazine, Amgen, Inc.; Bristol-Myers Squibb; and Takeda Oncology

Please click here to register for this event.

Thursday April 28, 2016 6:00pm - 7:30pm
Hemisfair Ballroom 3 200 E Market St, San Antonio, TX 78205

6:00pm

The Evolving State of Relapsed/Refractory Multiple Myeloma Treatment
In 2015 four new agents were approved for the treatment of multiple myeloma (MM) in the salvage setting, equipping oncology health professionals with more therapeutic options than ever before. But for oncology nurses, this progress also brings the challenge of managing new treatment-related toxicities. Through the use of iPad-based–learning elements, this interactive symposium will provide current information that will help oncology nurses maximize treatment outcomes for patients with relapsed/refractory MM.

Support for this activity has been provided through educational grants from Amgen, Bristol-Myers Squibb, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Please click here to register for this event.

6:00pm

Non-Small Cell Lung Cancer Grand Rounds (Part 3 of an 8-Part CNE Series): Nursing and Physician Investigators Discuss Cases from Their Practices
This unique symposium focused on the management of non-small cell lung cancer is part of an integrated series during which invited nursing faculty members will present actual patient cases from their practices, along with patient-provided lifestyle footage of themselves carrying out daily functions. No didactic presentations will be included, although relevant clinical research and data slides will augment moderated panel discussions designed to assess optimal therapeutic and supportive care strategies for each case. The panel will feature both medical oncologist and nurse experts to ensure that diverse perspectives emerge.

Moderator:
Neil Love, MD

Faculty:
Sarah B Goldberg, MD, MPH
Yale Cancer Center
New Haven, Connecticut
John V Heymach, MD, PhD
The University of Texas MD
Anderson Cancer Center
Houston, Texas

Amanda E Magnoli, ANP-BC, AOCNP
New England Cancer Specialists
Scarborough, Maine

Additional faculty to be announced

This activity is supported by educational grants from Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology and Novartis Pharmaceuticals Corporation.

Please click here to register for this event. 

 
Friday, April 29
 

6:00am

Breast Cancer Grand Rounds (Part 4 of an 8-Part CNE Series): Nursing and Physician Investigators Discuss Cases from Their Practices
This unique symposium focused on the management of breast cancer is part of an integrated series during which invited nursing faculty members will present actual patient cases from their practices, along with patient-provided lifestyle footage of themselves carrying out daily functions. No didactic presentations will be included, although relevant clinical research and data slides will augment moderated panel discussions designed to assess optimal therapeutic and supportive care strategies for each case. The panel will feature both medical oncologist and nurse experts to ensure that diverse perspectives emerge.

Moderator:
Neil Love, MD

Faculty:
Kimberly L Blackwell, MD
Duke Cancer Institute
Durham, North Carolina

Joyce O’Shaughnessy, MD
Baylor-Charles A Sammons Cancer Center
Dallas, Texas

Emily Olson, MSN, RN, CNP
Mayo Clinic, Rochester, Division of Medical Oncology
Rochester, Minnesota

Jennie Petruney, ANP-BC
North Carolina Cancer Hospital
Chapel Hill, North Carolina

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, Lilly and Novartis Pharmaceuticals Corporation.

Please click here to register for this event. 

6:00am

EGFR Mutation-Positive Metastatic NSCLC: A First Step in Choosing the Right Treatment for the Right Patient*
This promotional non-CNE symposium, sponsored by Boehringer Ingelheim Pharmaceuticals, Inc., will provide an opportunity to learn more about metastatic NSCLC with common EGFR mutations, including biomarker testing, treatment options, and supportive care via clinical case studies.  

This program is sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.

6:00am

TKI-related Side Effects: Patient Coping Strategies*
Review strategies for managing common side effects of tyrosine kinase inhibitors (TKIs)  • Explore practical approaches and best practices for optimizing patient care  • Discuss techniques for monitoring and improving adherence with oral therapy for patients on TKIs  

This ancillary program is presented by Bayer and held in conjunction with the ONS's 41st Annual Congress (PP-550-US-0261)

Please click here to regsister for this event. 

11:15am

Deletion 17p and BCL-2 Overexpression: Genetic Abnormalities and Their Role in Malignant Cell Survival
The evasion of apoptosis, a hallmark of cancer, results from an imbalance in the components and complex interactions of the BCL-2 family of proteins.  Anti-apoptotic proteins such as BCL-2 may block cell death in hematologic malignancies including chronic lymphocytic leukemia (CLL).  Additionally, a genetic abnormality, deletion 17p, is associated with poor prognosis in CLL patients.  This symposium discusses the BCL-2 pathway, the clinical significance of deletion 17p, and treatment options in deletion 17p CLL patients.

Sponsored by AbbVie-Genentech

Friday April 29, 2016 11:15am - 12:15pm
Learning Hall Theater 4 200 E Market St, San Antonio, TX 78205

11:15am

Identifying and Managing Patients With Intermediate or High-risk Myelofibrosis
Maureen E. Thyne, RPA-C
Physician Assistant II –
Outpatient Leukemia Service
Weill Cornell Medical College
New York, NY

This program is sponsored by Incyte Corporation

Friday April 29, 2016 11:15am - 12:15pm
Learning Hall Theater 1 200 E Market St, San Antonio, TX 78205

11:15am

Improving Progression-Free Survival in Patients With GEP-NETs
Join Ipsen Biopharmaceuticals, Inc., for Improving Progression-Free Survival in Patients With GEP-NETs —an educational program that discusses clinical data regarding a treatment option, as well as resources to facilitate the interactions between nurses and their patients with GEP-NETs. This is a promotional program sponsored by Ipsen Biopharmaceuticals, Inc. The information presented will be consistent with FDA guidelines. 

Ipsen Biopharmaceuticals, Inc.

Friday April 29, 2016 11:15am - 12:15pm
Learning Hall Theater 3 200 E Market St, San Antonio, TX 78205

11:15am

Nursing Considerations for Management of Your Patient’s Skin Toxicities, Clinical Management of EGFR Inhibitor Associated Dermatologic Toxicities: Considerations for Nurses
This program will review the unique group of dermatologic toxicities associated with EGFR inhibitors; their frequency, grading, timing, and recommended prevention and reactive management strategies; along with practical communication starters to empower nurses to proactively advocate improved patient care.  © Lilly USA, LLC 2016. All rights reserved.

© Lilly USA, LLC 2015. ALL RIGHTS RESERVED.

Friday April 29, 2016 11:15am - 12:15pm
Learning Hall Theater 2 200 E Market St, San Antonio, TX 78205

12:15pm

Improving Patient Outcomes Through Personalizing Care in the Management of Chemotherapy-Induced Nausea and Vomiting
CINV impairs quality of life, negatively impacts nutritional status, can delay treatment, elevates the risk of nonadherence to chemotherapeutic therapy, and increases the use of healthcare resources. Therapeutic advances have resulted in better understanding of CINV pathophysiology and how therapy for CINV can be personalized. Join us to learn the most up-to-date therapies for managing CINV as well as expert insights into the pathophysiology and classification of CINV. 

Chair 

Richard J. Gralla, MD, FACP
Professor of Medicine
Albert Einstein College of Medicine
Jacobi Medical Center
Bronx, NY


Faculty

Rebecca Clark-Snow, RN, BSN, OCN
Clinical Nurse Coordinator
The University of Kansas Cancer Center
Westwood, KS

 

Cynthia N. Rittenberg, RN, MN, AOCN, FAAN
Rittenberg Oncology Consulting
Metairie, LA 


This activity is supported by an educational grant from Helsinn Therapeutics (US), Inc. and TESARO.


Please click here to register for this event. 

12:15pm

Ovarian Cancer Grand Rounds (Part 5 of an 8-Part CNE Series): Nursing and Physician Investigators Discuss Cases from Their Practices
This unique symposium focused on the management of ovarian cancer is part of an integrated series during which invited nursing faculty members will present actual patient cases from their practices, along with patient-provided lifestyle footage of themselves carrying out daily functions. No didactic presentations will be included, although relevant clinical research and data slides will augment moderated panel discussions designed to assess optimal therapeutic and supportive care strategies for each case. The panel will feature both medical oncologist and nurse experts to ensure that diverse perspectives emerge.

Moderator:
Neil Love, MD

Faculty:
Paula J Anastasia, RN, MN, AOCN
Cedars-Sinai Medical Center
Los Angeles, California

Lisa B Arvine, RN, MSN, ANP-BC, WHNP-BC
Dana-Farber Cancer Institute
Boston, Massachusetts

Robert L Coleman, MD
Department of Gynecologic Oncology and Reproductive Medicine
Houston, Texas

Kathleen Moore, MD
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Genentech BioOncology.

Please click here to register for this event. 

12:15pm

Transforming Blood Cancer Care, the Role of Clinical Trials and CAR T-Cell Therapy
There has been great progress in treatment, but for most blood cancers, there is no cure and better therapies are needed. In this symposium, new and evolving treatment strategies will be discussed, including how the heterogeneous nature of blood cancers dictates treatment and prognosis, the role of clinical trials, and the evolving role of CAR T-cell therapy.  Cases will focus on acute myeloid leukemia (AML) and on diffuse large B-cell lymphoma (DLBCL). 

Sponsored by The Leukemia & Lymphoma Society and supported by educational grants from Kite Pharma, Inc. and Stemline Therapeutics, Inc.

Please click here to register for this event. 

Friday April 29, 2016 12:15pm - 1:45pm
Hemisfair Ballroom 200 E Market St, San Antonio, TX 78205

12:15pm

Working Group to Personalize Multidisciplinary Care in Patients with Lung Cancer: Updates and Evolving Concepts for Nurses
The Working Group to Personalize Multidisciplinary Care in Patients with Lung Cancer: Updates and Evolving Concepts for Nurses symposium features oncology nurses and physician peers discussing challenges in testing for epidermal growth factor receptor (EGFR) mutations, choosing an EGFR tyrosine kinase inhibitor (TKI), managing adverse events, addressing resistance to therapy, and the role of next-generation EGFR TKIs. Interactive case-based discussions will allow attendees to apply clinical evidence and expert opinion to patient care scenarios.

Co-Chairs 

 

Benjamin Levy, MD
Assistant Professor, Icahn School of Medicine
Medical Director, Thoracic Oncology Program, Mount Sinai Health Systems
Associate Director, Cancer Clinical Trials Office, Mount Sinai Hospital
Mount Sinai Hospital
New York, NY   

 

Karen Lee, MSN, FNP-BC
Mount Sinai Hospital
New York, NY 


Faculty 

 

Laura Brennan FNP-c, AOCNP
Division of Hematology & Oncology
UC Davis Medical Center
Sacramento, CA   

 

Ann Culkin, RN, OCN
Department of Nursing
Office Practice Nurse, Outpatient Thoracic Service
Memorial Sloan Kettering Cancer Center
New York, NY   

 

Alexander E. Drilon, MD
Thoracic Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY   

 

Jonathan Riess, MD, MS
Assistant Professor of Medicine
Division of Hematology Oncology
UC Davis Comprehensive Cancer Center
Sacramento, CA 


This activity is supported by educational grants from AstraZeneca. 

Please click here to register for this event. 

1:45pm

Bendeka: An Overview
Please join us for a presentation that will focus on BENDEKA™ (bendamustine hydrochloride) Injection, a new bendamustine formulation.

Teva Oncology

Friday April 29, 2016 1:45pm - 2:45pm
Learning Hall Theater 4 200 E Market St, San Antonio, TX 78205

1:45pm

Exploring the Differences in Disease and Care for African Americans Living with Multiple Myeloma
Learn about the differences in disease for African Americans living with multiple myeloma, including epidemiology and disparities in care and outcomes. Explore strategies to improve care for this group of patients. Receive disease education specific for your African American patients living with multiple myeloma. Join Celgene in “Standing in the Gaap” for our patients!  

This program is supported by Celgene Corporation.

Friday April 29, 2016 1:45pm - 2:45pm
Learning Hall Theater 1 200 E Market St, San Antonio, TX 78205

1:45pm

KYPROLIS® (carfilzomib) for Injection: Overview of Dosing, Safety Information, and Patient Counseling
This learning hall is meant to educate healthcare providers on KYPROLIS® along with dosing, administration and safety information.

This program is presented by Onyx Pharmaceuticals Inc. an Amgen Subsidiary

Friday April 29, 2016 1:45pm - 2:45pm
Learning Hall Theater 3 200 E Market St, San Antonio, TX 78205

1:45pm

Novel Delivery for the Treatment of Breakthrough Pain in Cancer (BTPc)
On behalf of Depomed, please join us to learn about a novel delivery system for the treatment of breakthrough cancer pain. The program will discuss the delivery system, appropriate dosing and titration, as well as appropriate patients for this treatment.

This program is sponsored by Depomed, Inc. 

Friday April 29, 2016 1:45pm - 2:45pm
Learning Hall Theater 2 200 E Market St, San Antonio, TX 78205

6:00pm

Guiding Patients on Their Treatment Journey With NINLARO® (ixazomib)
Provide nurses/advanced practice providers with an overview of the NINLARO patient treatment journey— from efficacy and safety to dosing and adherence.

This program is sponsored by Takeda Oncology.

Please click here to register for this event. 

6:00pm

Guiding Patients on Their Treatment Journey With NINLARO® (ixazomib)
Provide nurses/advanced practice providers with an overview of the NINLARO patient treatment journey— from efficacy and safety to dosing and adherence.

This program is sponsored by Takeda Oncology.

Please click here to register for this event. 

6:00pm

6:00pm

Patient Care in Metastatic CRPC: The Role of XTANDI® (enzalutamide) Capsules
Please join us for an Astellas Pharma US, Inc. and Medivation, Inc. presentation of XTANDI® in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Haydee Kapin, DNP, ARNP, AOCN, from the University of Miami will walk you through an overview of mCRPC, discuss considerations for the treatment of patients with mCRPC, present patient cases, and review the use of XTANDI and important safety information. We are looking forward to your attendance.

This program is sponsored by Astellas / Medivation

6:00pm

Shining Light on Pancreatic Cancer: Keeping You Up-to-Date and In the Know
Continued awareness and education is needed! In 2016 Pancreatic cancer is expected to claim the lives of 41,780 individuals and reports the lowest survival rate of any major cancer. Are you armed with the facts and knowledge in the advances and treatment of this disease?    Advances in treatment provide hope but also increase the complexity of care for the patients. This activity will provide a look at the clinical application of new and emerging therapeutic options for advanced metastatic pancreatic cancer as well as examine steps nurses can take to assure a patient centered approach to treatment.

Supported by educational grants from Celgene Corporation and Aduro Biotech

Please click here to register for this event.

6:00pm

Lymphoma and Chronic Lymphocytic Leukemia Grand Rounds (Part 6 of an 8-Part CNE Series): Nursing and Physician Investigators Discuss Cases from Their Practices
This unique symposium focused on the management of Hodgkin and non-Hodgkin lymphomas, including chronic lymphocytic leukemia, is part of an integrated series during which invited nursing faculty members will present actual patient cases from their practices, along with patient-provided lifestyle footage of themselves carrying out daily functions. No didactic presentations will be included, although relevant clinical research and data slides will augment moderated panel discussions designed to assess optimal therapeutic and supportive care strategies for each case. The panel will feature both medical oncologist and nurse experts to ensure that diverse perspectives emerge.

Moderator:
Neil Love, MD

Faculty:
Michelle A Fanale, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Amy Goodrich, CRNP-AC
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland

John P Leonard, MD
Weill Cornell Medical College
New York, New York

Additional faculty to be announced

This activity is supported by educational grants from Abbvie Inc, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Pharmacyclics Inc and Seattle Genetics.

Please click here to register for this event. 

6:30pm

 
Saturday, April 30
 

6:00am

Expert Perspectives in Understanding Chemotherapy Induced Nausea and Vomiting (CINV): Practical Issues and Considerations for Nurses
Despite the availability of numerous treatment options, chemotherapy induced nausea and vomiting (CINV) remains an important problem for both clinicians and patients. This interactive symposium will provide oncology nurses with information that will help them to better evaluate patient-specific and chemotherapy-specific risk factors associated with CINV, differentiate among available treatment options, assess emerging approaches for CINV prevention and management, formulate the optimal treatment plan for CINV prophylaxis, and summarize safety concerns associated with anti-emetogenic agents. 

This activity is supported by an unrestricted educational grant provided by Heron Therapeutics

Please click here to register for this event. 

6:00am

LONSURF® (trifluridine and tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer

Please join us for a breakfast symposium and overview of LONSURF® (trifluridine and tipiracil) hosted by Taiho Oncology. Mollie Reed, MSN RN ACNP-BC, from Tennessee Oncology in Nashville, Tennessee, will discuss LONSURF® and provide key information regarding this oral chemotherapy. We hope you will join us for this engaging event.

Sponsored by Taiho Oncology

Saturday April 30, 2016 6:00am - 7:30am
Hemisfair Ballroom 200 E Market St, San Antonio, TX 78205

6:00am

Melanoma Grand Rounds (Part 7 of an 8-Part CNE Series): Nursing and Physician Investigators Discuss Cases from Their Practices
This unique symposium focused on the management of melanoma is part of an integrated series during which invited nursing faculty members will present actual patient cases from their practices, along with patient-provided lifestyle footage of themselves carrying out daily functions. No didactic presentations will be included, although relevant clinical research and data slides will augment moderated panel discussions designed to assess optimal therapeutic and supportive care strategies for each case. The panel will feature both medical oncologist and nurse experts to ensure that diverse perspectives emerge.

Moderator:
Neil Love, MD

Faculty:
Adil Daud, MD
University of California
San Francisco, California

Rene Gonzalez, MD
University of Colorado Comprehensive
Cancer Center
Aurora, Colorado

Jason J Luke, MD
The University of Chicago Medicine
Chicago, Illinois

Kathleen Madden, RN, MSN, FNP-BC, AOCNP
NYU Langone Medical Center
New York University
New York, New York

Additional faculty to be announced

This activity is supported by educational grants from Amgen Inc, Genentech BioOncology, Merck, and Novartis Pharmaceuticals Corporation.


Please click here to register for this event. 

6:00am

Strategies for Preventing Lymphedema. Striving to Improve Every Patient’s Quality of Life *
Monitoring for the early detection of lymphedema using advancements in technology.  L-Dex is an objective assessment tool, which is quick, easy, painless, and could create significant savings in survivorship care.  Empower your patients to take control.

ImpediMed acknowledges support of this non-CNE symposium.

Please click here to register for this event. 

11:15am

11:15am

Caring for Your OPDIVO® (nivolumab) Patients With Previously Treated Metastatic NSCLC
This presentation will focus on the efficacy and safety of OPDIVO in patients with previously treated metastatic NSCLC across squamous and non-squamous histologies, with a special focus for nurses on the management of immune-mediated adverse reactions.

This program is sponsored by Bristol-Myers Squibb

Saturday April 30, 2016 11:15am - 12:15pm
Learning Hall Theater 4 200 E Market St, San Antonio, TX 78205

11:15am

Overview of IMLYGIC ® (talimogene laherparepvec) Suspension for Injection
This learning hall is meant to educate healthcare providers on IMLYGIC® along with dosing, administration, and safety information. The session will also include a demonstration of the injection technique for healthcare providers.

This program is presented by Amgen, Inc.

Saturday April 30, 2016 11:15am - 12:15pm
Learning Hall Theater 2 200 E Market St, San Antonio, TX 78205

11:15am

Supportive Care Issues in the Oncology Clinical Practice
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems for therapeutic molecules that improve the quality of patients’ lives.  Using proprietary sublingual spray technology and our capabilities to develop pharmaceutical cannabinoids, we work to address the clinical shortcomings of existing pharmaceutical products.  This product theater will discuss supportive care issues in the oncology clinical practice including   • Cancer chemotherapy-induced nausea and vomiting in patients who have failed to respond adequately to conventional antiemetic treatments  • Breakthrough Cancer Pain and Potential Solutions  

This program is sponsored by INSYS Therapeutics

Saturday April 30, 2016 11:15am - 12:15pm
Learning Hall Theater 3 200 E Market St, San Antonio, TX 78205

12:15pm

Bladder Cancer Grand Rounds (Part 8 of an 8-Part CNE Series): Nursing and Physician Investigators Discuss Cases from Their Practices
This unique symposium focused on the management of bladder cancer is part of an integrated series during which invited nursing faculty members will present actual patient cases from their practices, along with patient-provided lifestyle footage of themselves carrying out daily functions. No didactic presentations will be included, although relevant clinical research and data slides will augment moderated panel discussions designed to assess optimal therapeutic and supportive care strategies for each case. The panel will feature both medical oncologist and nurse experts to ensure that diverse perspectives emerge.

Moderator:
Neil Love, MD

Faculty:
Anastassia Daskalova, ANP
Mount Sinai Hospital
New York, New York


Matthew D Galsky, MD
Icahn School of Medicine at Mount Sinai
New York, New York

Leonard G Gomella, MD
Sidney Kimmel Cancer Center Network
Philadelphia, Pennsylvania

Matthew Galsky, MD
Mount Sinai Hospital
New York, New York

Elizabeth R Plimack, MD, MS
Fox Chase Cancer Center, Temple Health
Philadelphia, Pennsylvania

Susan K Roethke, CRNP, MSN, ANP-BC, AOCNP
Fox Chase Cancer Center
Philadelphia, Pennsylvania

This activity is supported by Genentech BioOncology.

Please click here to register for this event. 

12:15pm

HALAVEN: Optimizing Care for Patients
This presentation will include a review of the HALAVEN’s updated indication and mechanism of action. HALAVEN has been approved as a treatment choice for metastatic breast cancer and advanced liposarcoma. HALAVEN acts on the tumor through a culmination of its tubulin based antimitotic action and biological effects on tumor vascularization and microenvironment.  

Vermont law prohibits, Minnesota law restricts, and Department of Veterans Affairs and Department of Defense policy prohibits Eisai from offering meals at speaker events to certain health care professionals. If you are licensed in either of those states, or employed by either agency, Eisai regrets that due to these restrictions, we will not be able to offer a meal in conjunction with this event. Additionally, Eisai is required by Massachusetts, Vermont, Washington DC, and the Federal Physician Payment Sunshine Act to disclose certain value transfers, eg, meals, provided to certain health care professionals. If you have questions regarding how Eisai tracks and reports this information, please contact Eisai at 1-855-643-4328. 

12:15pm

REVLIMID® (lenalidomide) Treatment For Patients With Deletion 5q Myelodysplastic Syndromes: A Nurse’s Perspective*
Please join us for a Celgene presentation of REVLIMID® in the treatment of del(5q) myelodysplastic syndromes (MDS). Sandra Kurtin, RN, MS, AOCN, ANP-C, from the University of Arizona Cancer Center will walk you through an overview of MDS, discuss considerations for the treatment of patients with MDS, present patient cases, and review the use of REVLIMID and important safety information. We are looking forward to your attendance. 

This program is sponsored by Celgene Corporation

12:15pm

The Nurse's Take on the Management of Myeloproliferative Neoplasms: Stories From the Front Lines of Patient Care
Oncology nurse professionals play a key role in the management of myeloproliferative neoplasms (MPNs), including diseases such as myelofibrosis (MF) and polycythemia vera (PV). This symposium will offer nurse professionals insight from their expert colleagues on the modern treatment of MPNs, the role of new agent classes such as JAK inhibitors, and recommendations on how to optimally educate patients on the nature and clinical burden of diseases such as MF or PV.

This activity is supported by an educational grant from Incyte Corporation.

Please click here to register for this event. 

Saturday April 30, 2016 12:15pm - 1:45pm
Hemisfair Ballroom 200 E Market St, San Antonio, TX 78205

1:45pm

Patient Management Considerations in the Treatment of Advanced Melanoma
There have been a lot of new developments recently regarding treatment options for advanced melanoma. Nurses play a critical role in patient management, and with the changed treatment paradigm, the management of patients also is evolving. At the conclusion of this session, attendees will have a better understanding of how to manage patients with advanced melanoma.

Objectives:

  • Provide an overview on advanced melanoma
  • Understand the clinical data of a treatment option for advanced melanoma
  • Discuss supportive strategies for managing patients given a treatment option for advanced melanoma

This program is presented by Merck & Co., Inc., in conjunction with American Medical Communications. No continuing nursing education (CNE) credit will be awarded.

Please join us onsite for first-come, first-served participation. Seating is limited. 

Saturday April 30, 2016 1:45pm - 2:45pm
Learning Hall Theater 1 200 E Market St, San Antonio, TX 78205

7:00pm

Caring for Patients With Advanced or Metastatic Cancer: Nursing Implications & Overview of a Treatment Option for Advanced Non-Small Cell Lung Cancer*
Please join us for a Celgene Corporation presentation of Abraxane.  Peter Bjerkerot, RN will walk you through an overview of lung cancer, discuss considerations for the treatment of patients with lung cancer, review updated data regarding the use of Abraxane and provide important safety information. We are looking forward to your attendance.

This program is supported by Celgene Corporation

7:00pm

Guiding Patients on Their Treatment Journey With NINLARO® (ixazomib)
Provide nurses/advanced practice providers with an overview of the NINLARO patient treatment journey— from efficacy and safety to dosing and adherence.

This program is sponsored by Takeda Oncology.

Please click here to register for this event. 

7:00pm

Guiding Patients on Their Treatment Journey With NINLARO® (ixazomib)
Provide nurses/advanced practice providers with an overview of the NINLARO patient treatment journey— from efficacy and safety to dosing and adherence.

This program is sponsored by Takeda Oncology.

Please click here to register for this event.